Format

Send to

Choose Destination
J Sex Med. 2016 Jun;13(6):994-9. doi: 10.1016/j.jsxm.2016.03.371. Epub 2016 May 6.

A European Network for the Investigation of Gender Incongruence: Endocrine Part.

Author information

1
Department of Endocrinology, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: m.dekker3@vumc.nl.
2
Department of Endocrinology, Ghent University Hospital, Ghent, Belgium.
3
Department of Endocrinology, VU University Medical Center, Amsterdam, The Netherlands.
4
Department of Medical Psychology, VU University Medical Center, Amsterdam, the Netherlands.
5
Center for Sexology and Gender, Ghent University Hospital, Ghent, Belgium.
6
Sexual Medicine and Andrology Unit, Department of Experimental, Clinical and Biomedical Sciences, University of Florence, Florence, Italy.
7
Department of Obstetrics and Gynaecology, VU University Medical Center.
8
Department of Endocrinology, Oslo University Hospital, Oslo, Norway.
9
Department of Endocrinology, Ghent University Hospital, Ghent, Belgium; Center for Sexology and Gender, Ghent University Hospital, Ghent, Belgium.

Abstract

INTRODUCTION:

Cross-sex hormone therapy is an essential part of gender affirming treatment of transgender individuals. Studies systematically describing the physical and psychological effects of hormonal treatment of transgender persons are scarce.

AIM:

The aim of the current protocol is to evaluate clinical and side-effects of cross-sex hormonal treatment in trans persons.

METHODS:

The European Network for the Investigation of Gender Incongruence (ENIGI) is a multicenter prospective study. Because of the relatively low prevalence of the condition and small number of specialized centers, international collaboration is warranted. Four European treatment centers, Ghent, Oslo, Florence, and Amsterdam, developed a common study and treatment protocol.

MAIN OUTCOME MEASURES:

Outcome measures include hormonal and metabolic parameters, bone density, secondary sex and anthropometric characteristics, and physical and psychological well-being.

RESULTS:

Thus far, 333 trans women and 343 trans men have been included in the ENIGI Endocrine protocol. The study is still ongoing.

CONCLUSION:

In recent years, the number of trans persons seeking gender affirming treatment has increased. However, well-designed prospective studies evaluating safety and effectiveness of current hormonal treatment protocols are lacking. Therefore we started the ENIGI collaboration. In this article we give a detailed description of the study protocol, objectives, and design of the ENIGI Endocrine protocol.

KEYWORDS:

Cross-Sex Hormonal Treatment; Gender Dysphoria; Prospective Cohort Study

PMID:
27162190
DOI:
10.1016/j.jsxm.2016.03.371
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center